Newsflash from ADA: Day 3

Incretin-based therapies are our focus in the Day 3 Newsflash from the 84th ADA Scientific Sessions. Ildiko Lingvay discusses their role in preventing the progression from prediabetes to diabetes. Michael Nauck, the pioneer of the incretin effect, examines the current evidence on the benefits and risks of GLP-1 receptor agonists in people with type 1 diabetes and obesity. EASD Honorary Secretary Tina Vilsbøll finishes off with her perspective on the role of incretin-based therapies in diabetes care and previews the upcoming EASD Annual Meeting in Madrid from 9 to 15 September.